Background
==========

Heart failure (HF) is a growing problem that puts a tremendous burden on health care facilities worldwide. Up to 70% of all patients with HF die within 5 years after their first hospital admission \[[@B1]\]. The most common cause of HF is coronary artery disease (CAD), including the acute coronary syndromes (ACS) of ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina (UA) \[[@B2]\]. The development of HF following ACS significantly worsens short-and long-term prognosis \[[@B3]\]. In developed countries, CAD is a major cause of HF, morbidity and mortality. Significant advances have been made over the last decade in therapeutic approaches to ACS, particularly the development of new antiplatelet therapies and recognition of the benefits of neurohumoral blockade. Nonetheless, ACS remains among the main causes of death in developing countries \[[@B3]\]. One factor contributing to the poor prognosis is development of HF and left ventricular dysfunction following myocardial infarction (MI) \[[@B4]\]. It is of utmost importance to identify patients at risk of developing HF at admission since it may influence immediate therapeutic choices and subsequent risk stratification strategies which consequently help improve prognosis, personalize patient care, optimize the use of healthcare resources and prevent HF and death.

The aim of this work was to describe the clinical characteristics, and in-hospital management/outcomes of ACS patients with HF in the United Arab Emirates, enrolled in the Gulf Registry of Acute Coronary Events (Gulf RACE) \[[@B5],[@B6]\]. We also evaluated HF impact on in-hospital mortality.

Methods
=======

Patients and data collection
----------------------------

Patients were selected from the Gulf Registry of Acute Coronary Events (Gulf RACE), a prospective multinational, multicentre registry of patients above 18 years of age hospitalized with the final diagnosis of ACS from various hospitals in 6 Middle Eastern countries, namely: Oman, United Arab Emirates (UAE), Qatar, Bahrain, Kuwait and Yemen \[[@B5]\]. Details of the Gulf RACE design and methods have been previously described \[[@B5]\]. There were no exclusion criteria. The recruitment in the pilot phase started from May 8, 2006, to June 6, 2006. Enrolment in the next phase of the registry started in January 29, 2007, and continued for 5 months till June 29, 2007. The present study included 1691 of 1697 patients hospitalized with an ACS across 18 hospitals in the UAE with complete data on HF (with HF: 356, 21.1%). These hospitals care for more than 85% of patients with ACS in the country. Demographic, historical, and clinical data as well as in-hospital outcomes were recorded by study physicians for all patients admitted with a diagnosis of ACS.

Definitions of the sets of variables collected from the patients, outcome parameters as well as the diagnosis of ACS types were done following the American College of Cardiology (ACC) clinical data standards \[[@B7]\], for example:

1\. DM: history of diabetes, regardless of duration of disease, need for antidiabetic agents, or a fasting blood sugar greater than 7 mmol/l or 126 mg/dl.

2\. Hypertension: documented by: 1. History of hypertension diagnosed and treated with medication, diet, and/or exercise, 2. Blood pressure greater than 140 mmHg systolic or 90 mmHg diastolic on at least 2 occasions and 3. Current use of antihypertensive pharmacological therapy.

3\. Hyperlipidemia: diagnosed and/or treated by a physician. National Cholesterol Education Program criteria include documentation of the following: 1. Total cholesterol greater than 200 mg/dl (5.18 mmol/l); or 2. Low-density lipoprotein (LDL) greater than or equal to 130 mg/dl (3.37 mmol/l); or 3. High-density lipoprotein (HDL) less than 40 mg/dl (1.04 mmol/l). Treatment is also initiated if LDL is greater than 100 mg/dl (2.59 mmol/l) in patients with known coronary artery disease, and this *would* qualify as hypercholesterolemia.

4\. Past revascularization: including CABG or PCI of any type (balloon angioplasty, atherectomy, stent, or other) done before the current admission with the dates noted.

5\. Prior CAD: includes history of angina before the current admission and if it existed more than 2 weeks before admission and/or within 2 weeks before admission. "Angina" refers to evidence or knowledge of symptoms before this acute event described as chest pain or pressure, jaw pain, arm pain, or other equivalent discomfort suggestive of cardiac ischemia. MI: the patient at least had 1 documented previous MI before admission with the date noted.

All the patients were assigned to one of the following categories: ST-elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), left bundle branch block myocardial infarction (LBB MI) and UA. These definitions take into account clinical presentation, ECG findings, and the results of serum biochemical markers of myocardial necrosis (troponin and CPK-MB). Following ACS incidents after admissions, serial of cardiac enzymes were recorded and the highest (peak) values were used in our paper. Particularly, UA was defined as ACS with normal biochemical markers of necrosis. Patients were categorized at the time of hospital admission according to the classification of Killip and Kimball \[[@B8]\] for signs of HF. Killip class (scale I--IV) is a risk stratification tool for patients after acute myocardial infarction (AMI); a low Killip class indicates a lower likelihood of death within the first 30 days than a high Killip class. Smokers were defined as smoking cigarettes or sheesha (water pipe) within 1 month prior to index admission. A positive family history of coronary heart disease was defined as evidence of this disease in a parent, sibling, or children before the age of 55 years. The protocols of this study were approved by the Al Ain Medical District Human Research Ethics Committee, Abu Dhabi and Dubai Health Authorities and the Ministry of Health. All patients gave informed written consent to participate and care was taken to ensure data anonymity.

Statistical analysis
--------------------

All data were analyzed with SPSS statistical software version 19.0 (Chicago, Illinois, USA). The comparison of continuous variables between patients with and without HF was performed using the Student t-test. Categorical variables were compared using the Pearson's chi-square test (or Fisher exact test for expected cells less than 5). Continuous variables with (approximately) normal distribution were expressed as mean ± SD. Multivariable backward stepwise logistic binary regression analysis was performed to estimate adjusted odds ratios (OR) of the potentially independent predictors (note: such predictors are not necessarily causes of outcome) of in-hospital HF adjusted for the following baseline covariates: age, gender, heart rate, smoking, DM, hypertension, hyperlipidemia, past revascularization including coronary artery bypasses graft surgery (CABG) or percutaneous coronary intervention (PCI) and prior coronary artery disease (CAD) including angina or myocardial infarction (MI).

Similarly, the association between HF and in-hospital mortality was examined using step-wise logistic regression models adjusting for the following covariates: age, gender, heart rate, smoking, DM, hypertension, hyperlipidemia, past revascularization including CABG or PCI and prior CAD including angina or MI. In all cases a P-value below 0.05 was considered statistically significant.

Results
=======

Patient population
------------------

The records of 1691 ACS patients represent the total sample of this study. Among these, 356 patients (21.1%) had HF at hospital admission. The clinical characteristics of the study sample, by HF diagnosis at hospital admission are shown in Table [1](#T1){ref-type="table"}. The mean age of the cohort was 52.5 ± 11.6 years. Patients with HF were significantly older than patients without HF (57.8 ± 13 vs. 51.2 ± 10.8 years; P \< 0.001), were less likely to be male (34.3% among females vs. 19.2% among males; P \< 0.001) and less likely to smoke (38.2% vs. 50.3%; P \< 0.001). Risk factors for coronary artery disease were more common in patients with HF as they were more often hypertensive (64.3% vs. 43.9%), hyperlipidemic (49.4% vs. 31.8%) and diabetic (51.1% vs. 36.2%) (P \< 0.001 for all comparisons). Furthermore, the HF group included a significantly higher number of patients with prior angina/MI and past PCI/CABG (50% vs. 34.2%; P \< 0.001, 18.8% vs. 14.1%; P = 0.018, respectively) compared to the non-HF group. Patients with HF were slightly less likely to have STEMI on admission, but the overall distribution of admission diagnoses was not statistically different between HF and other patients. Patients with HF had a higher heart rate on presentation versus those without HF (97 ± 27.2 vs. 81.4 ± 19.8 beats/min; P \< 0.001).

###### 

Demographic and baseline characteristics of the studied acute coronary syndrome patients according to the presence of HF (n = 1691)

  **Variable**                                      **HF**          **Non-HF**      **P-value**
  -------------------------------------------- ----------------- ----------------- -------------
  Age, mean ± SD, years                           57.8 ± 13.0       51.2 ± 10.8      \< 0.001
  Male                                            284 (79.8)        1197 (89.7)      \< 0.001
  Hypertension                                    229 (64.3)        586 (43.9)       \< 0.001
  Hyperlipidemia                                  176 (49.4)        425 (31.8)       \< 0.001
  Diabetes mellitus                               182 (51.1)        483 (36.2)       \< 0.001
  Smoking                                         136 (38.2)        672 (50.3)       \< 0.001
  Family history of CAD                            39 (11.0)        221 (16.6)         0.008
  Prior angina or MI                              178 (50.0)        457 (34.2)       \< 0.001
  Past PCI or CABG                                 67 (18.8)        188 (14.1)         0.030
  [ACS diagnosis]{.ul}:                                                                0.66
  STEMI                                           141 (39.6)        572 (42.9)            
  NSTEMI                                           81 (22.8)        302 (22.6)            
  UA                                              131 (36.8)        453 (33.9)            
  LBBB MI                                           3 (0.8)           8 (0.6)             
  [Admission characteristics]{.ul}:                                                       
  Killip class:                                                                           
  I                                                   \-            1335 (100)            
  II                                              221 (62.0)            \-                
  III                                             102 (28.7)            \-                
  IV                                               33 (9.3)             \-                
  ST deviation                                    287 (80.8)         998 (749)         0.021
  Heart rate, mean ± SD, beats/min                 97 ± 27.2        81.4 ± 19.8      \< 0.001
  Systolic blood pressure, mean ± SD, mm Hg      145.7 ± 40.5      141.7 ± 27.9        0.028
  Diastolic blood pressure, mean ± SD, mm Hg      87.2 ± 23.7       85.6 ± 17.1        0.167
  [Laboratory investigations]{.ul}^\*^:                                                   
  Peak CPK, mean ± SD, (U/l)                    1269.9 ± 1930.5   1295.2 ± 1941.3      0.167
  Peak CPK-MB, mean ± SD, (U/l)                  99.1 ± 157.9       96.4 ± 135         0.109
  Peak troponin, mean ± SD, (μg/l)^†^             19.2 ± 79.3       15.8 ± 55.9        0.581
  Percent with LVEF ≤ 40%                        138/282 (49)      700/959 (73)      \< 0.001

^\*^Values were log~10~ transformed to approximate normality for the independent sample t-test.

^†^Peak troponin I or T (depending on recruiting centre).

Figures in parentheses are percentages.

Abbreviations: *HF* heart failure, *SD* standard deviation, *CAD* coronary artery disease, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass surgery, *NSTEMI* non-ST-segment elevation myocardial infarction, *STEMI* ST-elevation myocardial infarction, *LBBB* left bundle branch block, *UA* unstable angina, *CPK* creatinine phosphokinase, *CPK-MB* creatine kinase-myocardial band isoenzyme.

### Medical management

Table [2](#T2){ref-type="table"} outlines medication use and in-hospital management of the study patients. Compared with patients without HF, the use of aspirin, beta-blockers, calcium channel blockers, diuretics and subcutaneous insulin was significantly lower among patients with HF during their hospital treatment (Table [2](#T2){ref-type="table"}). At discharge, the use of beta-blockers, calcium channel blockers, statins, nitrates, diuretics, antiarrythmic agents, digoxin and warfarin was significantly higher among patients with HF (Table [2](#T2){ref-type="table"}). Moreover, Patients with HF were more likely to undergo invasive cardiac procedures than patients without HF.

###### 

In-hospital and discharge management of the studied ACS patients with and without HF (n = 1691)

                                             **HF**     **Non-HF**    **P-value**
  --------------------------------------- ------------ ------------- -------------
  [In-hospital medical treatment:]{.ul}                                     
  Aspirin                                  344 (96.6)   1328 (99.5)    \< 0.001
  Clopidogrel                              336 (94.4)   1290 (96.6)      0.061
  IV HEP                                   48 (13.5)    204 (15.3)       0.451
  LMW HEP                                  311 (87.4)   1154 (86.4)      0.726
  GP                                       132 (37.1)   534 (40.0)       0.329
  BB                                       156 (43.8)   995 (74.5)     \< 0.001
  ACE                                      231 (64.9)   900 (67.4)       0.375
  AIIRB                                     18 (5.1)     57 (4.3)        0.562
  CCB                                      40 (11.2)     98 (7.3)        0.022
  Statins                                  329 (92.4)    1268 (95)       0.068
  Nitrates                                 268 (75.3)   934 (70.0)       0.056
  Diuretics                                242 (68.0)   158 (11.8)     \< 0.001
  SQ INS                                   160 (44.9)   368 (27.6)     \< 0.001
  IV INS                                    15 (4.2)     33 (2.5)        0.104
  [Discharge medical treatment:]{.ul}                                       
  Aspirin                                  321 (90.2)   1293 (97.0)    \< 0.001
  Clopidogrel                              290 (81.5)   1105 (82.8)      0.812
  BB                                       258 (72.5)   1148 (86.0)    \< 0.001
  ACE                                      252 (70.8)   999 (74.8)       0.193
  AIIRB                                     30 (8.4)     84 (6.3)        0.151
  CCB                                      43 (12.1)     90 (6.7)        0.001
  Statins                                  320 (90.9)   1273 (95.4)      0.001
  Nitrates                                 181 (51.0)   543 (40.7)     \< 0.001
  Diuretics                                208 (58.4)   142 (10.7)     \< 0.001
  Antiarrythmic agents                      21 (6.0)     14 (1.0)      \< 0.001
  Digoxin                                   16 (4.5)      6 (0.4)      \< 0.001
  Warfarin                                  15 (4.2)     15 (1.1)      \< 0.001
  [In-hospital procedures:]{.ul}                                            
  Echocardiography                         260 (73.0)   846 (63.4)       0.001
  PCI                                       9 (2.5)      13 (1.0)        0.025
  IABP                                      10 (2.8)     11 (0.8)        0.006
  [In-hospital outcomes:]{.ul}                                              
  Death                                     26 (7.3)      8 (0.6)      \< 0.001
  Cardiogenic shock                        44 (12.4)     22 (1.7)      \< 0.001
  Infarction                                16 (4.5)     26 (2.0)        0.011
  Stroke                                    5 (1.4)       4 (0.3)        0.023

Figures in parentheses are percentages.

Abbreviations: *DM* diabetes mellitus, *IV HEP* intravenous heparin, *LMW HEP* low molecular weight heparin, *GP* glycoprotein IIb/IIIa inhibitors, *BB* beta-blockers, *ACE* angiotensin-converting enzyme inhibitors, *AIIRB* angiotensin II receptor blockers, *CCB* calcium channel blockers, *SQ Insulin* subcutaneous insulin, *IV Insulin* intravenous insulin, *PCI* percutaneous coronary intervention, *IABP* Intra-aortic balloon pump.

Predictors of HF
----------------

Table [3](#T3){ref-type="table"} shows that the odds of HF increases by 3.4% per year of age (OR = 1.034; 95% CI: 1.021-1.047; P \< 0.001). Furthermore, patients with a history of hyperlipidemia were 1.5 times (OR = 1.539; 95% CI: 1.096-2.162; P = 0.013) more likely to present with HF than those without history of dyslipidemia. The risk of HF increased by 2.7% (OR = 1.027; 95% CI: 1.021-1.034; P \< 0.001), for every 1-beat-per-minute increase in heart rate. Finally, the model also showed that having diabetes mellitus (DM) increased the risk of HF by 42% (OR = 1.425; 95% CI: 1.047-1.938; P = 0.024).

###### 

Independent predictors of in-hospital HF using multivariable logistic regression

  **Criteria**     **OR**   **In-hospital HF**    **P**
  ---------------- -------- -------------------- ----------
  Age              1.034    1.021-1.047          \< 0.001
  hyperlipidemia   1.539    1.096-2.162          0.013
  Heart rate       1.027    1.021-1.034          \< 0.001
  Prior CAD        1.322    0.949-1.841          0.100
  DM               1.425    1.047-1.938          0.024

Abbreviation: *HF* heart failure, *OR* odds ratio, *CI* confidence interval, *CAD* coronary artery disease including angina or myocardial infarction *(MI)*, *DM* diabetes mellitus.

The variables that were dropped out of the multivariable logistic regression using the stepwise-backward elimination method included gender, smoking, hypertension and past revascularization (CABG/PCI).

Heart failure and adverse outcomes including in-hospital mortality
------------------------------------------------------------------

Major bleed (n = 15) and stroke (n = 9) were rare outcomes. Stroke was significantly associated with in-hospital mortality, even after adjustment for HF (P \< 0.001). Table [4](#T4){ref-type="table"} indicates that HF was significantly associated with in-hospital mortality (OR = 11.821; 95% CI: 5.385-25.948; P \< 0.001). The in-hospital mortality rate for male patients was substantially lower than the mortality rate for female patients (OR = 0.419; 95% CI: 0.195-0.902; P \< 0.033; using stepwise (backward selection) logistic regression).

###### 

Relationship between HF and in-hospital mortality using multivariable logistic regression

  **Criteria**   **OR**   **In-hospital mortality**   **P**
  -------------- -------- --------------------------- ----------
  HF             11.821      5.385-25.948             \< 0.001
  Gender         0.419       0.195-0.902              0.033
  Heart rate     1.013       1.000-1.026              0.068

Abbreviation: *HF* heart failure, *OR* odds ratio, *CI* confidence interval.

The variables that were dropped out of the multivariable logistic regression using the stepwise-backward elimination method included age, smoking, diabetes mellitus, hypertension, hyperlipidemia, past revascularization (CABG/PCI) and prior coronary artery disease (CAD) include angina or (MI).

Discussion
==========

The overall incidence of HF complicating ACS in our study was 21% (less so in males which represented 87.6% of the study population). This rate of HF is lower than reported in some previous studies of HF after AMI \[[@B9],[@B10]\] but similar to several other ones \[[@B11]-[@B13]\]. Since there is no definitive diagnostic test for HF, these differences may well be due to varying definitions of HF among studies, exclusion criteria or as in the present study, inclusion of all patients with ACS, or could be due to different delays in seeking care thereby not receiving timely diagnosis or optimal therapies. It was observed that one in four ACS patients from six Middle Eastern countries in the entire GULF RACE cohort had HF \[[@B11]\]. In this study and using only the UAE data from the GULF RACE, we observed that one in five patients with ACS had HF during admission. This high rate of HF patients with ACS could be due to the high prevalence of DM in the region \[[@B14],[@B15]\]. There is an increasing recognition that diabetic patients suffer from diabetic cardiomyopathy, including AMI and HF, which was originally described in 1972 on the basis of observations in four diabetic patients who presented with HF without evidence of hypertension, CAD, valvular or congenital heart disease \[[@B16]\]. Not surprisingly DM was also associated with HF in our study although our methodology precludes definitive causal interpretations. Most likely, because of the proinflammatory, and prothrombotic states associated with DM, diabetic patients with ACS are at high risk of subsequent cardiovascular events with poorer outcome and higher mortality rates \[[@B17]-[@B19]\]. This study also shows that HF is a common complication associated with all forms of ACS. Patients with ACS complicated by HF were more likely to die in the hospital or experience other in-hospital complications such as cardiogenic shock, infarction or stroke, although it is unclear from our logistic regression analyses whether this is because HF was the direct cause of in-hospital death (and other complications) in our patients or just a sign of substantial cardiac damage. Of note is that in-hospital mortality in our study of HF patients was 7.3%, which is relatively high. In-hospital mortality in large US registries was about 4% \[[@B20],[@B21]\], whereas in the European registries it ranged from 3.8% (ESC-HF Pilot) to 6.7% (EHFS II) and 7.1% (FINN-AKVA) \[[@B22]-[@B24]\]. There was a lower frequency of PCI and use of beta-blockers in the patients with HF. While the lower use of beta-blockers may be explained by the difficulty of starting such therapy early in patients with HF, the reason for the low rate of cardiac catheterization in these patients is uncertain.

The strengths of this investigation include its national perspective, the complete spectrum of ACSs experienced by the large number of patients studied and the use of standardized criteria for defining ACS and hospital outcomes. However, as with any observational registry-type study, the present findings have limitations. Although this registry includes 18 hospitals throughout the UAE, participating sites may not be representative of the whole country. Furthermore, post admission variables analyses related to physician discretion (medications, interventions) may be strongly influenced by unmeasured confounders. Our analysis is also limited by the lack of adequate follow up data on long term mortality and morbidity and it is possible that some patients were misclassified according to the Killip and Kimball \[[@B8]\] classification for signs of HF. Finally, the standard practice management of ACS in the participating hospitals were initially, predominantly conservative. There were few PCI facility centers and hardly any primary PCI center with an established interventional cardiology program (24 h/7 days) which has an important impact upon the incidence and severity of HF.

Conclusions
===========

In conclusion, in this cohort of patients with ACS in the UAE, HF complicates one-fifth of cases and was associated with age, heart rate, hyperlipidemia and DM. In-hospital mortality rate was associated with HF and gender. Further studies are needed to better risk-stratify patients with HF for more analysis as well as having information about prior history of HF and outcomes of post-hospital discharge in order to optimize the use of medications and cardiovascular interventions for this serious condition.
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